ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED

Zhejiang Wecome Pharmaceutical Company Limited

300878

CNE1000047P9

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
16.75 ^CNY	-2.67%		-7.97%	-33.98%

05-22	Zhejiang Wecome Pharmaceutical Company Limited Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024	CI
04-28	Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Zhejiang Wecome Pharmaceutical Company Limited Approved Cash Dividend for the Year 2021

June 07, 2022 at 08:33 pm

Zhejiang Wecome Pharmaceutical Company Limited announced that at its Annual General Meeting of 2021 on 06 June 2022, approved Cash dividend/10 shares (tax included) of CNY 5.40000000 for the year 2021.

Latest news about Zhejiang Wecome Pharmaceutical Company Limited

Zhejiang Wecome Pharmaceutical Company Limited Announces Final Cash Dividend on A Shares for the Year 2023, Payable on 29 May 2024	05-21	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024	04-28	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023	04-19	CI
Tranche Update on Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback Plan announced on February 7, 2024.	02-27	CI
Zhejiang Wecome Pharmaceutical Company Limited's Equity Buyback announced on February 7, 2024, has closed with 2,739,026 shares, representing 1.89% for CNY 50 million.	02-26	CI
Zhejiang Wecome Pharmaceutical Company Limited announces an Equity Buyback for CNY 50 million worth of its shares.	02-07	CI
Zhejiang Wecome Pharmaceutical Company Limited authorizes a Buyback Plan.	02-06	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023	29/10/23	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023	28/08/23	CI
Certain A Shares of Zhejiang Wecome Pharmaceutical Company Limited are subject to a Lock-Up Agreement Ending on 24-AUG-2023.	23/08/23	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2023	27/04/23	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022	27/04/23	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2022	27/10/22	CI
Zhejiang Wecome Pharma to Issue $95 Million Convertible Bonds	12/10/22	MT
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022	29/08/22	CI
Hangzhou Haishan Pharmaceutical Equipment Co., Ltd. announced that it expects to receive CNY 20 million in funding from Zhejiang Wecome Pharmaceutical Company Limited	17/07/22	CI
Zhejiang Wecome Pharmaceutical Company Limited Announces Final Profit Distribution Plan to Be Implemented on A Shares for the Year 2021, Payable on 17 June 2022	13/06/22	CI
Zhejiang Wecome Pharmaceutical Company Limited Approved Cash Dividend for the Year 2021	07/06/22	CI
Zhejiang Wecome Pharmaceutical Company Limited Proposes Final Cash Dividend for the Year 2021	29/04/22	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Full Year Ended December 31, 2021	28/04/22	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2022	28/04/22	CI
LBX Pharmacy Chain Joint Stock Company singed an Asset Purchase Agreement to acquire a 71.9% stake in Hunan Huairen Great Health Industry Development Co., Ltd. from group of sellers for CNY 1.6 billion.	06/03/22	CI
Zhejiang Wecome Pharmaceutical Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2021	27/10/21	CI
Zhejiang Jingning Oujiang Capsule Co., Ltd. announced that it expects to receive CNY 8.92 million in funding from Zhejiang Wecome Pharmaceutical Company Limited and other investors	26/10/21	CI
Zhejiang Wecome Pharmaceutical Company Limited completed the acquisition of 70% of stake in Zhejiang Jingning Oujiang Capsule Co., Ltd. from Wang Shiguo and Wang Linsu.	14/09/21	CI

Chart Zhejiang Wecome Pharmaceutical Company Limited

Duration

Period

Chart Zhejiang Wecome Pharmaceutical Company Limited

More charts

Company Profile

Zhejiang Wecome Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of modern Chinese medicine and western medicine. The Company's main products include Yinhuang dripping pills, motherwort soft capsules, motherwort dispersible tablets, Guci capsules, Fengliao Changweikang dispersible tablets, ginseng Jianpi tablets and other Chinese patent medicines, as well as western medicines such as roxithromycin soft capsules. Its production dosage forms cover hard capsules, tablets, granules, soft capsules, and pills. The Company mainly conducts its businesses in the China market.

Sector

Pharmaceuticals

Calendar

26/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ZHEJIANG WECOME PHARMACEUTICAL COMPANY LIMITED	-33.98%	335M
ELI LILLY AND COMPANY	+38.51%	727B
NOVO NORDISK A/S	+33.05%	599B
JOHNSON & JOHNSON	-6.23%	354B
MERCK & CO., INC.	+18.78%	328B
ABBVIE INC.	+1.35%	277B
ASTRAZENECA PLC	+16.00%	243B
NOVARTIS AG	+8.09%	205B
ROCHE HOLDING AG	-5.77%	203B
AMGEN INC.	+6.19%	164B